For the twelve months ended Mar 31, 2026, BioRestorative Therapies Inc. reported $357.9K of revenue and -$11.06M of net income.
BRTX revenue was $23.2K in fiscal Q1 2026 (ended Mar 31, 2026), down 7.3% from a year earlier and up 18.2% from the prior quarter. For the full fiscal 2025 it was $359.7K, down 10.3% from fiscal 2024. Compound annual growth was +36.1% over 5 years and -5.4% over 10 years. It rose in 6 of the last 10 fiscal years.
BRTX net income was -$2.15M in fiscal Q1 2026 (ended Mar 31, 2026), compared with -$5.34M a year earlier. For the full fiscal 2025 it was -$14.24M, compared with -$8.98M in fiscal 2024.
BRTX diluted EPS was -$0.12 in fiscal Q1 2026 (ended Mar 31, 2026). For the full fiscal 2025 it was -$1.58, compared with -$1.16 in fiscal 2024.
BRTX free cash flow was -$2.49M in fiscal Q4 2025 (ended Dec 31, 2025), compared with -$2.36M a year earlier. For the full fiscal 2025 it was -$10.91M, compared with -$8.34M in fiscal 2024.
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $359.7K | $401.0K | $145.8K | $119.8K | $46.0K | $77.0K | $130.0K | $111.0K | $81.0K | $36.4K |
| Cost of revenue | $23.8K | $28.1K | - | - | - | - | - | - | - | $102 |
| Gross profit | $335.9K | $372.9K | $145.8K | - | - | - | - | - | $81.0K | $36.3K |
| Research and development | $10.09M | $6.71M | $4.03M | $3.51M | $729.1K | $876.8K | $1.72M | $1.51M | $2.15M | $2.88M |
| Selling, general and admin | $5.89M | $5.22M | $11.33M | $15.58M | $25.62M | $1.79M | $4.61M | $4.02M | $3.90M | $3.25M |
| Operating income | -$15.65M | -$11.56M | -$15.22M | -$18.97M | -$26.31M | -$2.75M | -$8.43M | -$7.65M | -$8.37M | -$7.79M |
| Pre-tax income | -$14.20M | -$8.98M | - | - | - | - | - | - | -$9.44M | -$8.64M |
| Net income | -$14.24M | -$8.98M | -$10.42M | -$13.22M | -$44.30M | -$11.27M | -$14.65M | -$12.52M | -$9.44M | -$8.64M |
| EPS, basic | -$1.58 | -$1.16 | -$2.47 | -$3.65 | -$37.30 | -$28.56 | -$0.66 | -$1.64 | -$1.74 | -$2.10 |
| EPS, diluted | -$1.58 | -$1.16 | -$2.47 | -$3.65 | -$37.30 | -$28.56 | -$0.66 | -$1.64 | -$1.74 | -$2.10 |
| Diluted shares | 9.0M | 7.8M | 4.2M | 3.6M | 1.2M | 394,705 | 22.3M | 7.6M | 5.4M | 4.1M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $1.51M | $547.9K | $884.4K | $1.71M | $21.03M | $3.06M | $1.7K | $117.5K | $451.7K | $31.8K |
| Short-term investments | $1.44M | $10.18M | $10.18M | $13.04M | - | - | - | - | - | - |
| Receivables | $15.5K | $188.4K | $19.3K | $16.0K | $5.0K | $17.0K | $32.0K | $29.0K | $38.0K | $6.0K |
| Current assets | $3.14M | $11.14M | $11.39M | $15.13M | $21.47M | $3.19M | $68.9K | $181.0K | $519.7K | $73.4K |
| Total assets | $4.08M | $12.28M | $12.61M | $16.43M | $22.45M | $4.35M | $1.47M | $1.19M | $1.76M | $1.58M |
| Current liabilities | $3.72M | $3.75M | $2.61M | $5.98M | $363.8K | $1.04M | $13.72M | $9.25M | $8.35M | $5.84M |
| Total debt | - | - | - | - | $250.0K | - | - | $4.15M | $3.66M | $2.16M |
| Total liabilities | - | $3.75M | $2.61M | $6.14M | $856.5K | $5.68M | $14.24M | $9.83M | $8.60M | $6.58M |
| Shareholders' equity | $356.7K | $8.53M | $10.00M | $10.29M | $10.78M | -$1.33M | -$12.78M | -$8.64M | -$6.84M | -$5.00M |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$10.79M | -$8.23M | -$6.43M | -$5.91M | -$3.33M | -$1.96M | -$6.92M | -$5.10M | -$3.85M | -$5.00M |
| Capital expenditures | $116.1K | $106.2K | $171.0K | $265.2K | $30.7K | - | $35.6K | $12.9K | $3.6K | $188.8K |
| Free cash flow | -$10.91M | -$8.34M | -$6.60M | -$6.18M | -$3.36M | - | -$6.95M | -$5.12M | -$3.86M | -$5.19M |
| Investing cash flow | $8.90M | $514.5K | $3.25M | -$13.40M | -$30.7K | - | -$35.6K | -$12.9K | -$3.6K | -$188.8K |
| Financing cash flow | $2.85M | $7.38M | $2.35M | - | $21.32M | $5.03M | $6.84M | $4.78M | $4.28M | $5.06M |
| Share repurchases | $0 | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | $3.33M | $2.81M | $7.78M | $12.61M | $23.11M | $691.7K | $1.66M | $2.40M | $3.60M | $2.54M |
| Depreciation and amortization | $210.0K | $189.1K | $165.7K | $120.5K | $89.1K | $121.4K | $217.4K | $240.4K | $259.3K | $258.4K |
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -10.3% | 175.0% | 21.7% | 160.4% | -40.3% | -40.8% | 17.1% | 37.0% | 122.8% | -94.2% |
| Gross margin | 93.4% | 93.0% | 100.0% | - | - | - | - | - | 100.0% | 99.7% |
| Operating margin | -4350.1% | -2881.6% | -10439.5% | -15838.1% | -57191.0% | -3574.1% | -6486.2% | -6889.8% | -10338.6% | -21414.0% |
| Net margin | -3959.4% | -2239.2% | -7145.2% | -11037.0% | -96311.5% | -14639.9% | -11267.6% | -11277.3% | -11660.1% | -23755.4% |
| Free cash flow margin | -3031.7% | -2078.9% | -4527.6% | -5157.2% | -7305.6% | - | -5349.5% | -4610.4% | -4762.3% | -14279.8% |
| Return on equity | -3992.2% | -105.3% | -104.1% | -128.5% | -410.9% | - | - | - | - | - |
| Return on assets | -349.1% | -73.1% | -82.6% | -80.5% | -197.3% | -259.3% | -999.0% | -1049.8% | -537.1% | -546.6% |
| Current ratio | 0.84 | 2.97 | 4.37 | 2.53 | 59.01 | 3.05 | 0.01 | 0.02 | 0.06 | 0.01 |
| Debt to equity | - | - | - | - | 0.02 | - | - | - | - | - |
| Line item | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.2K | $19.6K | $11.8K | $303.3K | $25.0K | $43.3K | $233.6K | $89.1K | $35.0K | $19.3K | $30.7K | $64.5K |
| Cost of revenue | $7.4K | $1.6K | $10.6K | $8.7K | $2.9K | $3.3K | $18.2K | $6.5K | $0 | - | - | - |
| Gross profit | $15.8K | $18.0K | $1.2K | $294.6K | $22.1K | $40.0K | $215.4K | $82.6K | $35.0K | $19.3K | $30.7K | $64.5K |
| Research and development | $1.93M | $2.63M | $2.59M | $2.23M | $2.65M | $1.70M | $1.45M | $1.45M | $1.06M | $1.09M | $809.8K | $902.9K |
| Selling, general and admin | $1.48M | $1.22M | $1.12M | $1.37M | $2.18M | $1.03M | $1.05M | $1.10M | $3.09M | $2.15M | $2.33M | $2.28M |
| Operating income | -$3.39M | -$3.83M | -$3.71M | -$3.31M | -$4.81M | -$2.69M | -$2.29M | -$2.47M | -$4.11M | -$3.22M | -$3.10M | -$3.12M |
| Net income | -$2.15M | -$3.21M | -$3.04M | -$2.66M | -$5.34M | -$1.64M | -$1.09M | -$4.03M | -$2.22M | -$2.30M | $4.77M | -$5.71M |
| EPS, basic | -$0.12 | -$0.31 | -$0.33 | -$0.30 | -$0.64 | -$0.20 | -$0.13 | -$0.50 | -$0.33 | - | $1.04 | -$1.47 |
| EPS, diluted | -$0.12 | -$0.31 | -$0.33 | -$0.30 | -$0.64 | -$0.20 | -$0.13 | -$0.50 | -$0.33 | - | $0.39 | -$1.47 |
| Diluted shares | 17.7M | - | 9.1M | 8.7M | 8.4M | - | 8.1M | 8.1M | 6.7M | - | 12.3M | 3.9M |
| Line item | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $3.11M | $1.51M | $602.4K | $1.56M | $1.23M | $547.9K | $1.49M | $2.25M | $1.16M | $884.4K | $2.44M | $1.78M |
| Short-term investments | $479.4K | $1.44M | $3.89M | $5.83M | $7.88M | $10.18M | $11.60M | $12.43M | $15.26M | $10.18M | $9.80M | $9.83M |
| Receivables | $13.3K | $15.5K | $13.4K | $15.0K | $25.0K | $188.4K | $165.0K | $27.4K | $35.0K | $19.3K | $39.3K | $25.0K |
| Current assets | $3.80M | $3.14M | $4.71M | $7.60M | $9.36M | $11.14M | $13.51M | $15.00M | $16.77M | $11.39M | $12.60M | $12.04M |
| Total assets | $4.64M | $4.08M | $5.64M | $8.52M | $10.33M | $12.28M | $14.57M | $16.12M | $17.95M | $12.61M | $13.80M | $13.30M |
| Current liabilities | $1.61M | $3.72M | $3.44M | $3.67M | $4.18M | $3.75M | $4.58M | $5.32M | $3.45M | $2.61M | $3.00M | $10.57M |
| Total liabilities | - | - | - | $3.67M | $4.18M | $3.75M | $4.58M | $5.32M | $3.45M | $2.61M | $3.04M | $10.66M |
| Shareholders' equity | $3.03M | $356.7K | $2.21M | $4.85M | $6.14M | $8.53M | $9.99M | $10.80M | $14.50M | $10.00M | $10.76M | $2.64M |
| Line item | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.81M | -$2.42M | -$2.90M | -$2.69M | -$2.78M | -$2.35M | -$1.70M | -$1.87M | -$2.32M | -$1.59M | -$1.18M | -$1.31M |
| Capital expenditures | - | $79.7K | $0 | $0 | $36.4K | $12.4K | $58.5K | - | - | $70.0K | $11.9K | $29.0K |
| Free cash flow | - | -$2.49M | -$2.90M | -$2.69M | -$2.82M | -$2.36M | -$1.76M | - | - | -$1.66M | -$1.19M | -$1.34M |
| Investing cash flow | $968.4K | $2.40M | $2.00M | $2.13M | $2.37M | $1.53M | $936.8K | $2.97M | -$4.93M | -$84.8K | -$21.4K | $819.0K |
| Financing cash flow | $4.44M | $923.2K | -$49.3K | $888.1K | $1.09M | -$126.3K | $0 | -$12.8K | $7.52M | $83.1K | $1.85M | - |
| Share repurchases | $0 | - | - | - | - | - | - | - | - | - | - | - |
| Stock-based compensation | $290.2K | $447.9K | $399.9K | $468.7K | $2.01M | $175.6K | $284.2K | $324.3K | $2.03M | $1.46M | $1.45M | $1.49M |
| Depreciation and amortization | $52.4K | $52.8K | $52.6K | $52.7K | $51.8K | $50.4K | $48.3K | $47.7K | $42.7K | $42.7K | $42.1K | $41.5K |
| Line item | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -7.3% | -54.7% | -94.9% | 240.4% | -28.6% | 124.4% | 660.9% | 38.1% | 11.8% | 421.6% | 5.9% | -9.3% |
| Gross margin | 68.1% | 91.7% | 10.4% | 97.1% | 88.4% | 92.3% | 92.2% | 92.7% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating margin | -14612.6% | -19516.8% | -31432.3% | -1089.8% | -19230.1% | -6212.8% | -979.0% | -2770.8% | -11740.7% | -16687.5% | -10112.2% | -4831.9% |
| Net margin | -9298.3% | -16365.5% | -25748.1% | -875.8% | -21359.2% | -3778.6% | -467.2% | -4521.4% | -6352.2% | -11937.8% | 15531.8% | -8851.8% |
| Free cash flow margin | - | -12728.8% | -24585.9% | -888.2% | -11260.7% | -5451.0% | -752.6% | - | - | -8590.6% | -3880.7% | -2082.4% |
| Current ratio | 2.35 | 0.84 | 1.37 | 2.07 | 2.24 | 2.97 | 2.95 | 2.82 | 4.86 | 4.37 | 4.20 | 1.14 |
Source: XBRL data BioRestorative Therapies Inc. files with the SEC, latest filing dated May 14, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-20, first reported Aug 14, 2015.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.